DXCM, a broken stock?
The stock is down 40% for three main reasons:
Market Share Loss to Competitors: The company lost significant market share to
ABT in the Medical Device Channel (MDC), contributing about $100 million to the guide down.
Slower New Patient Growth: There was a noticeable slowdown in new patient uptake, adding $125 million to the projected loss. Although the company is seeing some improvements, the market remains cautious.
Faster Than Expected Rebates: Rebates from Medicare occurred faster than anticipated, resulting in lower prices for adopters sooner than expected, accounting for a $75 million decrease in guidance.
Dexcom (DXCM) has caught my interest due to its recent significant price action. After a 40% gap down, which occurred overnight in after-hours and pre-market trading, the daily chart now shows a promising setup. The earnings release led to a small spinning top candle, not exceeding the daily ATR, contrary to what many traders might have anticipated. The stock closed with an impressive relative volume of 10.07, setting a key support level at $62.34 where sellers failed to push the price lower.
This scenario is a classic opportunity for hedge funds looking for long-only trades, as the stock has lost 40% of its valuation overnight, presenting a potentially low-risk buying opportunity. I plan to swing trade DXCM next week, ideally waiting for any further liquidity sweeps to the downside to be quickly bought up, such as a wick down to $63 or a break below the prior day's low of $62.34, only to be bought up again. This would trigger my entry, either before close or at the next open, with a stop loss at the daily pivot low. This trade requires patience and courage, as the stock is displaying signs of capitulatory price action, but not sheer panic.
The potential for a reversal is strong given the exaggerated sell-off and the significant volume indicating substantial interest at these levels.
Market Share Loss to Competitors: The company lost significant market share to
ABT in the Medical Device Channel (MDC), contributing about $100 million to the guide down.Slower New Patient Growth: There was a noticeable slowdown in new patient uptake, adding $125 million to the projected loss. Although the company is seeing some improvements, the market remains cautious.
Faster Than Expected Rebates: Rebates from Medicare occurred faster than anticipated, resulting in lower prices for adopters sooner than expected, accounting for a $75 million decrease in guidance.
Dexcom (DXCM) has caught my interest due to its recent significant price action. After a 40% gap down, which occurred overnight in after-hours and pre-market trading, the daily chart now shows a promising setup. The earnings release led to a small spinning top candle, not exceeding the daily ATR, contrary to what many traders might have anticipated. The stock closed with an impressive relative volume of 10.07, setting a key support level at $62.34 where sellers failed to push the price lower.
This scenario is a classic opportunity for hedge funds looking for long-only trades, as the stock has lost 40% of its valuation overnight, presenting a potentially low-risk buying opportunity. I plan to swing trade DXCM next week, ideally waiting for any further liquidity sweeps to the downside to be quickly bought up, such as a wick down to $63 or a break below the prior day's low of $62.34, only to be bought up again. This would trigger my entry, either before close or at the next open, with a stop loss at the daily pivot low. This trade requires patience and courage, as the stock is displaying signs of capitulatory price action, but not sheer panic.
The potential for a reversal is strong given the exaggerated sell-off and the significant volume indicating substantial interest at these levels.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.